Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
On Tuesday, Pliant Therapeutics Inc (NASDAQ:PLRX) announced topline data from a Phase 2a PET Imaging trial of bexotegrast (PLN-74809) evaluating change in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis (IPF) characterized by excessive collagen deposition in the lung.
周二，Pliant Therapeutics Inc（纳斯达克股票代码：PLRX）公布了bexotegrast（PLN-74809）2a期PET成像试验的主要数据，该试验评估了以肺部胶原蛋白沉积过多为特征的特发性肺纤维化（IPF）患者肺部胶原蛋白总水平的变化。
Bexotegrast-treated patients showed reduced total lung collagen post-treatment as measured by positron emission tomography (PET) imaging, compared to increased total lung collagen in the placebo group, suggesting potential reversal of fibrosis.
与安慰剂组的肺胶原蛋白总量增加相比，通过正电子发射断层扫描（PET）成像测量，接受Bexotegrast治疗的患者在治疗后肺部胶原蛋白总量减少，这表明纤维化可能逆转。
After 12 weeks of treatment, bexotegrast-treated patients showed a reduction in standardized uptake value (SUV) of 68GA-CBP8 in the lung compared to an increase in placebo.
经过12周的治疗，与安慰剂的增加相比，接受bexotegrast治疗的患者肺中 68GA-CBP8 的标准摄取值（SUV）有所降低。
68GA-CBP8 is a PET ligand that binds to type 1 collagen.
68GA-CBP8 是一种与 1 型胶原蛋白结合的 PET 配体。
This reduction in SUV indicates reduced total lung collagen in the treated group, suggesting a potential reversal of fibrosis.
SUV的减少表明接受治疗组的肺部胶原蛋白总量减少，这表明纤维化有可能逆转。
Bexotegrast-treated patients demonstrated improvements in forced vital capacity (FVC) and reduced cough severity compared to placebo.
与安慰剂相比，接受Bexotegrast治疗的患者表现出强迫肺活量（FVC）的改善和咳嗽的严重程度降低。
The trial's exploratory efficacy endpoints assessed changes in FVC forced vital capacity percent predicted (FVCpp), patient-reported cough severity, and fibrosis biomarkers.
该试验的探索性疗效终点评估了FVC强制肺活量预测百分比（fvCPP）、患者报告的咳嗽严重程度和纤维化生物标志物的变化。
Bexotegrast-treated patients experienced improved lung function, as measured by FVC and FVCpp, with a clear separation from placebo.
根据FVC和fvCPP的测量，接受Bexotegrast治疗的患者的肺功能得到改善，与安慰剂明显分开。
Across all time points, bexotegrast-treated patients experienced reduced patient-reported cough severity compared to placebo patients.
在所有时间点上，与安慰剂患者相比，接受bexotegrast治疗的患者报告的咳嗽严重程度有所降低。
At weeks 4 and 12, bexotegrast-treated patients demonstrated a reduction in circulating biomarkers integrin beta-6 and PRO-C3 relative to placebo.
在第 4 周和第 12 周，与安慰剂相比，经过 bexotegrat 治疗的患者表现出循环生物标志物整合素 β-6 和 PRO-C3 的含量有所减少。
PRO-C3, a serum biomarker of type III collagen synthesis, is elevated in patients with IPF and associated with progressive disease.
PRO-C3 是 III 型胶原蛋白合成的血清生物标志物，在 IPF 患者中升高，与进行性疾病有关。
Bexotegrast was well tolerated at 160 mg over 12 weeks of treatment, with no serious adverse events reported.
在12周的治疗中，160毫克的Bexotegrast耐受性良好，没有报告严重的不良事件。
Most frequently reported treatment-emergent adverse events were mild in severity with no trial discontinuations.
最常报告的治疗紧急不良事件的严重程度较轻，没有中止试验。
Price Action: PLRX shares are up 1.3% at $13.90 at last check Tuesday.
价格走势：周二最后一次检查时，PLRX股价上涨1.3％，至13.90美元。
Photo: Shutterstock
照片：Shutterstock